• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV 预防研究经验:男男性行为者和跨性别有色人种。

HIV Prevention Research Experiences Among Men Who Have Sex With Men and Transgender Persons of Color.

机构信息

Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School, Newark, USA.

出版信息

J Racial Ethn Health Disparities. 2023 Aug;10(4):1542-1548. doi: 10.1007/s40615-022-01340-4. Epub 2022 Jun 9.

DOI:10.1007/s40615-022-01340-4
PMID:35679012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9179221/
Abstract

PURPOSE

Black and Latinx MSM and transgender POC disproportionately experience new HIV diagnoses. Determining effective HIV prevention methods requires the inclusion of these communities in research and thorough post-trial experience evaluations. This study sought to evaluate the experiences of Black and Latinx MSM and transgender POC in HIV prevention research and identify facilitators and barriers to continued trials participation.

METHODS

A survey was developed in partnership with the community engagement team based on emerging themes during research participant check-ins with the team. The survey was built in REDCap and distributed to participants via text message. The survey assessed experiences with the research process time commitments, study responsibilities, compensation, experiences with Truvada®, characteristics of the research study team and site, barriers to continued study participation, willingness to participate in future studies, and overall satisfaction. All statistical analysis was completed in Stata.

RESULTS

Forty-four participants were enrolled in the study. Most participants (98%) were satisfied with their experiences in HIV prevention research. Job or school schedules were the most frequently cited barrier to study participation while Truvada® provision and adequate study visit compensation, length, number, and frequency were facilitators. Participants reported that research staff made them feel comfortable when talking about sexual behaviors, alcohol use, mental health, drug use, housing problems, violence in relationships, and legal problems.

CONCLUSIONS

Evaluating the experiences of key communities in HIV prevention research can help identify barriers and facilitators to clinical trials engagement and improve the design of future trials.

摘要

目的

黑人和拉丁裔男男性行为者和跨性别少数群体(POC)不成比例地经历新的 HIV 诊断。确定有效的 HIV 预防方法需要将这些群体纳入研究,并对试验后经验进行彻底评估。本研究旨在评估黑人和拉丁裔男男性行为者和跨性别 POC 在 HIV 预防研究中的经验,并确定继续参与试验的促进因素和障碍。

方法

一项调查是在社区参与团队的合作下开发的,该调查是基于团队与研究参与者定期交流中出现的主题。该调查是在 REDCap 中构建的,并通过短信分发给参与者。该调查评估了研究过程中的经验、时间承诺、研究责任、补偿、特鲁瓦达®的体验、研究团队和地点的特征、继续参与研究的障碍、参与未来研究的意愿以及总体满意度。所有统计分析均在 Stata 中完成。

结果

共有 44 名参与者入组本研究。大多数参与者(98%)对他们在 HIV 预防研究中的经验感到满意。工作或学校时间表是参与研究的最常见障碍,而特鲁瓦达®的提供以及充足的研究访问补偿、长度、数量和频率是促进因素。参与者报告说,研究人员在谈论性行为、饮酒、心理健康、药物使用、住房问题、关系中的暴力和法律问题时,让他们感到舒适。

结论

评估 HIV 预防研究中关键群体的经验可以帮助确定参与临床试验的障碍和促进因素,并改进未来试验的设计。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bdc/10322760/fe55cbbe70af/40615_2022_1340_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bdc/10322760/d86ceed80039/40615_2022_1340_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bdc/10322760/fe55cbbe70af/40615_2022_1340_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bdc/10322760/d86ceed80039/40615_2022_1340_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bdc/10322760/fe55cbbe70af/40615_2022_1340_Fig2_HTML.jpg

相似文献

1
HIV Prevention Research Experiences Among Men Who Have Sex With Men and Transgender Persons of Color.HIV 预防研究经验:男男性行为者和跨性别有色人种。
J Racial Ethn Health Disparities. 2023 Aug;10(4):1542-1548. doi: 10.1007/s40615-022-01340-4. Epub 2022 Jun 9.
2
HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.HPTN 083-02:影响注射用 PrEP 依从性和保留率的因素。
J Int AIDS Soc. 2024 May;27(5):e26252. doi: 10.1002/jia2.26252.
3
The feasibility of recruiting and retaining men who have sex with men and transgender women in a multinational prospective HIV prevention research cohort study in sub-Saharan Africa (HPTN 075).在撒哈拉以南非洲进行一项多国前瞻性艾滋病毒预防研究队列研究(HPTN 075)中,招募和保留男男性行为者和跨性别女性的可行性。
J Int AIDS Soc. 2020 Oct;23 Suppl 6(Suppl 6):e25600. doi: 10.1002/jia2.25600.
4
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.恩曲他滨和丙酚替诺福韦艾拉酚胺与恩曲他滨和富马酸替诺福韦二吡呋酯用于 HIV 暴露前预防(DISCOVER):一项随机、双盲、多中心、阳性对照、3 期、非劣效性临床试验的主要结果。
Lancet. 2020 Jul 25;396(10246):239-254. doi: 10.1016/S0140-6736(20)31065-5.
5
HIV prevention and HIV care among transgender and gender diverse youth: design and implementation of a multisite mixed-methods study protocol in the U.S.HIV 预防和跨性别及性别多样化青年中的 HIV 护理:美国多地点混合方法研究方案的设计和实施
BMC Public Health. 2019 Nov 15;19(1):1531. doi: 10.1186/s12889-019-7605-4.
6
HIV burden and correlates of infection among transfeminine people and cisgender men who have sex with men in Nairobi, Kenya: an observational study.肯尼亚内罗毕跨性别女性和与男性发生性关系的顺性别男性中的 HIV 负担和感染相关因素:一项观察性研究。
Lancet HIV. 2021 May;8(5):e274-e283. doi: 10.1016/S2352-3018(20)30310-6. Epub 2021 Feb 22.
7
Barriers and facilitators to HIV testing among young men who have sex with men and transgender women in Kingston, Jamaica: a qualitative study.牙买加金斯敦男男性行为者和跨性别女性中艾滋病毒检测的障碍与促进因素:一项定性研究
J Int AIDS Soc. 2017 Apr 4;20(1):21385. doi: 10.7448/IAS.20.1.21385.
8
"All We Had Were the Streets": Lessons Learned From a Recreation-Based Community Health Space for Young Black MSM and Trans Women Across the HIV Prevention and Care Continuum.“我们仅拥有街道”:从一个面向年轻黑人男男性行为者和跨性别女性的、基于娱乐活动的社区健康空间在艾滋病预防和护理连续过程中所汲取的经验教训
AIDS Educ Prev. 2018 Aug;30(4):309-321. doi: 10.1521/aeap.2018.30.4.309.
9
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP).积极策略优化新型 HIV 暴露前预防(PrEP)药物试验中黑人、西班牙裔/拉丁裔、跨性别和非二元个体的参与度。
PLoS One. 2022 Jun 3;17(6):e0267780. doi: 10.1371/journal.pone.0267780. eCollection 2022.
10
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.HIV 暴露前预防在跨性别女性中的应用:iPrEx 试验的亚组分析。
Lancet HIV. 2015 Dec;2(12):e512-9. doi: 10.1016/S2352-3018(15)00206-4. Epub 2015 Nov 6.

本文引用的文献

1
Patient-centered practices for engaging transgender and gender diverse patients in clinical research studies.以患者为中心的实践,让跨性别和性别多样化的患者参与临床研究。
BMC Med Res Methodol. 2021 Oct 1;21(1):202. doi: 10.1186/s12874-021-01328-4.
2
Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP).跨性别女性在接受长效注射型卡替拉韦(CAB-LA)用于 HIV 暴露前预防(PrEP)时,对定制注射递药策略的障碍、促进因素和偏好。
AIDS Behav. 2021 Dec;25(12):4180-4192. doi: 10.1007/s10461-021-03357-y. Epub 2021 Jul 3.
3
Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities.
美国三个城市中男男性行为者对多种未来HIV暴露前预防产品的使用偏好。
J Int AIDS Soc. 2021 Jan;24(1):e25664. doi: 10.1002/jia2.25664.
4
House Ball Community Leaders' Perceptions of HIV and HIV Vaccine Research.住宅球社区领袖对艾滋病毒及艾滋病毒疫苗研究的看法。
Int J MCH AIDS. 2020;9(1):136-145. doi: 10.21106/ijma.331. Epub 2020 Feb 13.
5
'It all dials back to safety': A qualitative study of social and economic vulnerabilities among transgender women participating in HIV research in the USA.“这一切都可以追溯到安全问题”:美国参与 HIV 研究的跨性别女性的社会和经济脆弱性的定性研究。
BMJ Open. 2020 Jan 19;10(1):e029852. doi: 10.1136/bmjopen-2019-029852.
6
Transgender Women's Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs).跨性别女性对潜在未来长效生物医学 HIV 预防策略的关注和偏好:以注射和植入式药物输送装置(IMDDs)为例。
AIDS Behav. 2020 May;24(5):1452-1462. doi: 10.1007/s10461-019-02703-5.
7
The REDCap consortium: Building an international community of software platform partners.REDCap 联盟:构建软件平台合作伙伴的国际社区。
J Biomed Inform. 2019 Jul;95:103208. doi: 10.1016/j.jbi.2019.103208. Epub 2019 May 9.
8
A Demographic Analysis of Racial/Ethnic Minority Enrollment Into HVTN Preventive Early Phase HIV Vaccine Clinical Trials Conducted in the United States, 2002-2016.2002-2016 年在美国开展的 HVTN 预防早期阶段 HIV 疫苗临床试验中,对少数族裔入组的人口统计学分析。
Public Health Rep. 2019 Jan/Feb;134(1):72-80. doi: 10.1177/0033354918814260. Epub 2018 Dec 5.
9
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.用于预防HIV的卡博特韦长效注射用混悬液的满意度和可接受性:来自ECLAIR试验的患者观点
HIV Clin Trials. 2018 Aug;19(4):129-138. doi: 10.1080/15284336.2018.1511346. Epub 2018 Nov 16.
10
Participant satisfaction with clinical trial experience and post-trial transitioning to HIV care in Kenya.肯尼亚参与者对临床试验体验及试验后转入艾滋病护理的满意度。
Int J STD AIDS. 2019 Jan;30(1):12-19. doi: 10.1177/0956462418791946. Epub 2018 Aug 29.